Pharmacological treatment for buerger's disease

Pharmacological treatment for buerger's disease

Author Cacione, Daniel G. Autor UNIFESP Google Scholar
Macedo, Cristiane R. Autor UNIFESP Google Scholar
Baptista-Silva, Jose C. C. Autor UNIFESP Google Scholar
Abstract Background Buerger's disease (thromboangiitis obliterans) is a non-atherosclerotic, segmental inflammatory pathology that most commonly affects the small and medium sized arteries, veins, and nerves in the upper and lower extremities. The etiology is unknown, but involves hereditary susceptibility, tobacco exposure, immune and coagulation responses. In many cases, there is no possibility of revascularization to improve the condition. Pharmacological treatment is an option for patients with severe complications, such as ischaemic ulcers or rest pain. Objectives To assess the effectiveness of any pharmacological agent (intravenous or oral) compared with placebo or any other pharmacological agent in patients with Buerger's disease. Search methods The Cochrane Vascular Trials Search Co-ordinator searched their Specialised Register (last searched in April 2015) and the Cochrane Register of Studies (Issue 3, 2015). The review authors searched trial registers and the European grey literature

screened reference lists of relevant studies, and contacted study authors and major pharmaceutical companies. Selection criteria Randomised controlled trials (RCTs) involving pharmacological agents used in the treatment of Buerger's disease. Data collection and analysis Two review authors, independently assessed the studies, extracted data and performed data analysis. Main results Five randomised controlled trials (total 602 participants) compared prostacyclin analogue with placebo, aspirin, or a prostaglandin analogue, and folic acid with placebo. No studies assessed other pharmacological agents such as cilostazol, clopidogrel and pentoxifylline or compared oral versus intravenous prostanoid. Compared with aspirin, intravenous prostacyclin analogue iloprost improved ulcer healing (risk ratio (RR) 2.65

95% confidence interval (CI) 1.15 to 6.11

98 participants

one study

moderate quality evidence), and helped to eradicate rest pain after 28 days (RR 2.28

95% CI 1.48 to 3.52

133 participants

one study

moderate quality evidence), although amputation rates were similar six months after treatment (RR 0.32

95% CI 0.09 to 1.15

95 participants

one study

moderate quality evidence). When comparing prostacyclin (iloprost and clinprost) with prostaglandin (alprostadil) analogues, ulcer healing was similar (RR 1.13

95% CI 0.76 to 1.69

89 participants

two studies

I-2 = 0%

very low quality evidence), as was the eradication of rest pain after 28 days (RR 1.57

95% CI 0.72 to 3.44

38 participants

one study

low quality evidence), while amputation rates were not measured. Compared with placebo, the effects of oral prostacyclin analogue iloprost were similar for: healing ischaemic ulcers (iloprost 200 mcg: RR 1.11

95% CI 0.54 to 2.29

133 participants

one study

moderate quality evidence, and iloprost 400 mcg: RR 0.90

95% CI 0.42 to 1.93

135 participants

one study

moderate quality evidence), eradication of rest pain after eight weeks (iloprost 200 mcg: RR 1.14

95% CI 0.79 to 1.63

207 participants

one study

moderate quality evidence, and iloprost 400 mcg: RR 1.11

95% CI 0.77 to 1.59

201 participants

one study

moderate quality evidence), and amputation rates after six months (iloprost 200 mcg: RR 0.54

95% CI 0.19 to 1.56

209 participants

one study, and iloprost 400 mcg: RR 0.42

95% CI 0.13 to 1.31

213 participants

one study). When comparing folic acid with placebo in patients with Buerger's disease and hyperhomocysteinaemia, pain scores were similar, there were no new cases of amputation in either group, and ulcer healing was not assessed (very low quality evidence). Treatment side effects such as headaches, flushing or nausea were not associated with treatment interruptions or more serious consequences. Outcomes such as amputation-free survival, walking distance or pain-free walking distance, and ankle brachial index were not assessed by any study. Overall, the quality of the evidence was very low to moderate, with few studies, small numbers of participants, variation in severity of disease of participants between studies and missing information regarding for example baseline tobacco exposure. Authors' conclusions Moderate quality evidence suggests that intravenous iloprost (prostacyclin analogue) is more effective than aspirin for eradicating rest pain and healing ischaemic ulcers in Buerger's disease, but oral iloprost is not more effective than placebo. Verylow and low quality evidence suggests there is no difference between prostacyclin (iloprost and clinprost) and the prostaglandin analogue alprostadil for healing ulcers and relieving pain respectively in severe Buerger's disease. Very-low quality evidence suggests there is no difference in pain scores and amputation rates between folic acid and placebo, in people with Buerger's disease and hyperhomocysteinaemia. High quality trials assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger's disease are needed.
Keywords Placebo-Controlled Trial
Thromboangiitis-Obliterans
Systemic-Sclerosis
Digital Ulcers
Double-Blind
Iloprost
Bosentan
Prostacyclin
Ischemia
Arteries
Language English
Sponsor Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK
Chief Scientist Office
Date 2016
Published in Cochrane Database Of Systematic Reviews. Hoboken, n. 3, p. CD011033, 2016.
ISSN 1469-493X (Sherpa/Romeo, impact factor)
Publisher Wiley
Extent CD011033
Origin http://dx.doi.org/10.1002/14651858.CD011033.pub3
Access rights Open access Open Access
Type Revisão
Web of Science ID WOS:000373475200044
URI http://repositorio.unifesp.br/handle/11600/49547

Show full item record




File

Name: WOS000373475200044.pdf
Size: 588.4Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account